Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
[PURPOSE] Thyroid carcinoma (TC) is a rare neoplasia of the endocrine system and account for about 2-3% of all human tumors.
APA
Elisei R, Romei C (2023). Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.. Endocrine, 81(2), 206-215. https://doi.org/10.1007/s12020-023-03368-w
MLA
Elisei R, et al.. "Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.." Endocrine, vol. 81, no. 2, 2023, pp. 206-215.
PMID
37195581
Abstract
[PURPOSE] Thyroid carcinoma (TC) is a rare neoplasia of the endocrine system and account for about 2-3% of all human tumors. According to their cell origin and histological features, different histotypes of thyroid carcinoma are described. Genetic alterations involved in the pathogenesis of thyroid cancer have been described and it has been shown that alterations of the RET gene are common events in all TC hystotypes. Aim of this review is to give an overview of the relevance of RET alterations in TC and to provide indications, timing and methodologies, for RET genetic analysis.
[METHODS] A revision of the literature has been performed and indications for the experimental approach for the RET analysis have been reported.
[CONCLUSIONS] The analysis of RET mutations in TC has a very important clinical relevance for the early diagnosis of the hereditary forms of MTC, for the follow-up of TC patients and for the identification of those cases that can benefit from a specific treatment able to inhibit the effect of mutated RET.
[METHODS] A revision of the literature has been performed and indications for the experimental approach for the RET analysis have been reported.
[CONCLUSIONS] The analysis of RET mutations in TC has a very important clinical relevance for the early diagnosis of the hereditary forms of MTC, for the follow-up of TC patients and for the identification of those cases that can benefit from a specific treatment able to inhibit the effect of mutated RET.
MeSH Terms
Humans; Carcinoma, Medullary; Clinical Relevance; Multiple Endocrine Neoplasia Type 2a; Proto-Oncogene Proteins c-ret; Proto-Oncogene Mas; Thyroid Neoplasms; Mutation
같은 제1저자의 인용 많은 논문 (3)
- Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in -Mutant Medullary Thyroid Cancer.
- Current perspectives on the management of patients with advanced -driven thyroid cancer in Europe.
- Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.